Haemonetics Corporation Stock 12‑Month Price Target Raised to $81, Implies 31% Upside
Analysts have raised the 12-month price target for Haemonetics Corporation (HAE) stock to $81, up from $80.2, with a range spanning $62 to $104 per share. This new target suggests a 31% potential upside based on the closing price of May 21. The consensus rating among 11 analysts remains a "Buy," with 8 Buy ratings and 3 Holds.
BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80
BofA Securities has upgraded its rating for Haemonetics (HAE) from Neutral to Buy, setting a new price target of $80. This upgrade comes as the analyst firm anticipates potential upside for Haemonetics due to improvements in its core businesses. The medical technology company specializes in solutions for blood and plasma collection, as well as hospital technologies.
Does Haemonetics (HAE) Have Enduring Growth Potential?
Aristotle Capital Boston, LLC's first-quarter 2026 investor letter highlighted Haemonetics Corporation (NYSE: HAE), a medical technology company, noting its strong competitive position in the plasmapheresis market and increased R&D investment as key value drivers. Despite a recent revenue decline tied to planned portfolio transitions, the fund believes these factors will create long-term shareholder value, even as the company's shares experienced a one-year decline. Haemonetics reported revenue of $346 million in Q4 2026, a 5% increase year-over-year.
Q3 2026 Haemonetics Corp Earnings Call Transcript
Haemonetics Corp (HAE) announced strong Q3 2026 results, raising its full-year guidance for revenue, earnings, and free cash flow. Plasma performance was a key driver, accelerating with 20% organic growth excluding CSL. Despite positive overall performance, the company faced challenges in its Interventional technology and Vascular closure segments.
Haemonetics (HAE) SVP granted RSUs while shares withheld to cover taxes
Haemonetics Corp's SVP of Human Resources, Laurie A. Miller, received a grant of 13,323 restricted stock units (RSUs) as part of her equity compensation. Concurrently, 948 shares were withheld at $56.29 per share to cover tax obligations related to the RSU vesting. Following these transactions, Miller directly holds 27,977 shares of Haemonetics common stock.
Haemonetics (NYSE: HAE) VP granted 2,220 RSUs, 197 shares withheld for tax
Haemonetics Corp's VP and Chief Accounting Officer, Maryanne Maunsell Farris, was granted 2,220 restricted stock units (RSUs) that vest in three equal annual installments. Concurrently, 197 shares were withheld to cover tax obligations related to RSU vesting. Following these transactions, Farris directly holds 4,281 shares, including unvested RSUs.
Haemonetics (HAE) EVP and General Counsel receives 28,424 RSUs, 2,913 shares withheld for taxes
Haemonetics Corporation's EVP and General Counsel, Michelle L. Basil, was granted 28,424 restricted stock units (RSUs) as part of the company's long-term incentive plan. The RSUs will vest over three years. Additionally, 2,913 shares were withheld at $56.29 each to cover tax obligations on previously vested RSUs, rather than being an open-market sale.
HAEMONETICS CORP Insider Trading Activity
Frank Chan, EVP and COO of Haemonetics Corp (HAE), received an equity award of 27,535 restricted stock units (RSUs) on May 15, 2026. On the same date, 546 shares were disposed of to cover tax obligations at $56.29 per share. After these transactions, Mr. Chan directly owned 32,936 shares, including previously unvested RSUs and shares acquired through an Employee Stock Purchase Plan.
Haemonetics (HAE) CEO receives 78,344 RSUs and has shares withheld for taxes
Haemonetics Corp's CEO, Christopher Simon, received a grant of 78,344 Restricted Stock Units (RSUs) which will vest over three years. Simultaneously, 9,681 shares were withheld to cover tax obligations from previously vested RSUs. Following these transactions, his direct holdings are reported to be in the hundreds of thousands of shares, including 497 shares purchased through an Employee Stock Purchase Plan.
Does Haemonetics' (HAE) Buyback-Funded Loss Quarter Hint at Shifting Earnings Quality Priorities?
Haemonetics Corporation reported a shift from profit to a net loss of US$20.15 million in Q4 2026, despite quarterly sales of US$346.35 million, and a full-year net income decline to US$97.31 million alongside a US$175 million share buyback. This performance raises questions about the company's earnings quality, capital allocation, and ability to meet prior expectations for margin expansion. The article emphasizes that while the buyback reduced shares by 6.34%, the focus now shifts to restoring margin momentum and addressing product execution challenges, particularly with VASCADE, to justify the capital return and achieve projected revenue and earnings growth by 2029.
Haemonetics (HAE) Valuation Check As Earnings Pressure And Options Volatility Raise Questions
Haemonetics (HAE) is currently undergoing a valuation check as earnings pressure and increased options volatility attract investor attention. Despite a 35.2% undervaluation according to Simply Wall St's fair value estimate of $86.90, the stock has seen a significant year-to-date decline, driven by mixed sentiment following recent earnings and buyback updates. Key drivers for potential upside include innovation in plasma collection systems and new software contracts, though competitive risks in other segments and dependence on U.S.-focused products remain watchpoints.
Is the Options Market Predicting a Spike in Haemonetics Stock?
The options market shows significant implied volatility for Haemonetics (HAE) stock, particularly for the June 18, 2026 $40.00 Call, suggesting investors anticipate a large price movement. Despite this options activity, analysts currently rate Haemonetics as a Zacks Rank #3 (Hold), with recent downward revisions in earnings estimates. This high implied volatility, coupled with analysts' cautious outlook, could indicate a potential trading opportunity for options traders who sell premium.
Haemonetics Corp (HAE) Shares Surge 5.5% -- What GF Score of 74 Tells Investors
Haemonetics Corp (HAE) saw its shares surge 5.5%, but despite this, the stock is considered "Significantly Undervalued" by GuruFocus' GF Value, trading 34.7% below its estimated intrinsic value. The company holds an overall GF Score of 74/100, driven by strong profitability and growth, yet it shows weak momentum and no recent insider transactions. Investors are advised to consider the potential for upside alongside risks and the lack of insider confidence.
Is the Options Market Predicting a Spike in Haemonetics Stock?
The options market, particularly the June 18, 2026 $40.00 Call, shows high implied volatility for Haemonetics (HAE), suggesting investors anticipate a significant price movement. However, despite this options activity, analysts currently rate Haemonetics as a Zacks Rank #3 (Hold), with recent earnings estimates trending downwards. This divergence suggests a potential trading opportunity for options traders, especially those who sell premium.
North Peak group files 13G/A, Haemonetics (NYSE: HAE) shows ≤5% ownership
North Peak group and related persons have filed an amended Schedule 13G/A, reporting that they collectively hold 5 percent or less of the common stock of Haemonetics Corp (NYSE: HAE). The filing is a joint statement by North Peak Capital Management, North Peak Capital GP, several North Peak funds, and Jeremy S. Kahan and Michael K. Kahan. This administrative disclosure clarifies ownership levels and includes disclaimers regarding beneficial ownership and group status, indicating no material change to company control.
Is the Options Market Predicting a Spike in Haemonetics Stock?
Investors in Haemonetics Corporation (HAE) should monitor the stock's options market, specifically the June 18, 2026 $40.00 Call, which recently exhibited high implied volatility. While high implied volatility often signals an expectation of significant price movement, Haemonetics currently holds a Zacks Rank #3 (Hold) in an industry ranked in the Bottom 39%, with recent analyst estimate revisions trending downwards. Options traders might interpret this volatility as an opportunity to sell premium, betting against large stock movements.
Haemonetics Corp at Bank of America Global Healthcare Conference Transcript
This article provides the transcript of Haemonetics Corp's presentation at the Bank of America Global Healthcare Conference on May 12, 2026. CEO Chris Simon discussed the company's performance, particularly after setting a new guide following their last long-range plan. The conference transcript captures the initial dialogue between the unidentified interviewer and Simon.
Why Haemonetics (HAE) Is Down 9.5% After Mixed FY26 Results And FY27 Outlook Reset
Haemonetics (HAE) recently reported mixed Q4 and full-year FY26 results, with quarterly sales up but a net loss, and full-year sales and net income down, leading to a 9.5% stock drop. Despite weaker GAAP results, adjusted revenue and earnings exceeded analyst expectations, and the company issued FY27 guidance focusing on organic growth, margin expansion, and new product launches. The company's investment narrative hinges on its core platforms offsetting margin pressure and product concentration risks, with new product adoptions like VASCADE MVP XL's expanded FDA labeling acting as key catalysts.
Haemonetics Q4 Earnings Call Highlights
Haemonetics (NYSE:HAE) reported strong fiscal fourth-quarter and full-year 2026 results, with revenue growth driven by its Plasma and Blood Management Technologies segments, despite challenges in Interventional Technologies. The company achieved adjusted earnings of $1.29 per share for the quarter and $4.96 for the full year, along with expanding margins and improved free cash flow. Haemonetics provided fiscal 2027 guidance forecasting continued revenue and margin growth, emphasizing its focused strategy on core platforms and innovation like Persona PLUS.
Haemonetics Corporation 2026 Q4 - Results - Earnings Call Presentation (NYSE:HAE) 2026-05-10
Haemonetics Corporation (NYSE:HAE) released its Q4 2026 earnings, reporting an EPS of $1.29, beating estimates by $0.02. The company also posted a revenue of $346.35 million, which represents a 4.76% year-over-year increase and exceeded expectations by $9.49 million. The accompanying slide deck for the earnings call was published on May 10, 2026.
Why Haemonetics (HAE) Is Down 9.5% After Mixed FY26 Results And FY27 Outlook Reset
Haemonetics Corporation saw its stock drop 9.5% after reporting mixed Q4 and full-year 2026 results, which included a net loss for the quarter despite adjusted revenue and earnings beating analyst expectations. The company provided fiscal 2027 guidance focusing on organic revenue growth, margin expansion, and new product launches, particularly an expanded FDA label for VASCADE MVP XL. Investors are currently weighing near-term margin pressure and product concentration risks against potential growth catalysts from new innovations.
Haemonetics Q4 Earnings Call Highlights
Haemonetics (NYSE:HAE) reported strong fiscal fourth-quarter and full-year 2026 results, with revenue exceeding expectations due to growth in Plasma and Blood Management Technologies, despite challenges in Interventional Technologies. The company achieved adjusted earnings of $1.29 per share for Q4 and $4.96 for the full year, driven by higher adjusted margins and strong free cash flow. Haemonetics provided fiscal 2027 guidance expecting continued revenue and margin growth, with a focus on Plasma, TEG, and reinvigorating vascular closure, while excluding revenue from the PerQseal Elite product due to uncertain FDA clearance timing.
Tax withholding trims Haemonetics (NYSE: HAE) CFO share position
Haemonetics EVP and CFO James DArecca had 655 shares of common stock withheld on May 1, 2026, at $59.26 per share to cover tax obligations from vesting restricted stock units. This was a tax-related disposition, not an open-market sale. After this transaction, DArecca directly owns 27,637 shares, including previously reported unvested RSUs.
A Look At Haemonetics (HAE) Valuation After Q4 Loss And Sector-Wide Medical Device Sell Off
Haemonetics (HAE) recently reported a Q4 loss and its stock valuation is under scrutiny following a sector-wide medical device sell-off. Despite trading below some valuation markers, the company faces shrinking margins and has a P/E ratio higher than its industry peers. The article discusses whether the current stock price presents a genuine opportunity or if the market has already factored in its future growth prospects.
Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript
Haemonetics Corporation reported Q4 2026 revenue of $346 million, up 9% organic ex-CSL, and adjusted EPS of $1.29, marking a strong end to a transformative fiscal year. The company provided fiscal year 2027 guidance with projected revenue growth of 4% to 7% and anticipated continued margin expansion, driven by strength in plasma and TEG products, and an expected reinvigoration of growth in vascular closure. Management expressed confidence in the durability of growth and the strategic repositioning of the company for higher growth and margins.
Haemonetics (HAE) One Off Loss And Margin Hit Challenge Bullish Earnings Narrative
Haemonetics (HAE) recently reported a Q4 FY2026 loss of US$0.44 basic EPS, despite US$346.4 million in revenue, driven by a significant US$84.7 million one-off loss that reduced its trailing net profit margin to 7.3%. This margin pressure, coupled with a 26x P/E ratio and modest 5% revenue growth, challenges a bullish narrative supported by a DCF fair value significantly higher than its current share price. The article highlights investor divergence between those who view the margin hit as temporary and those who see it as a warning sign due to product dependency and elevated debt.
Needham Maintains Haemonetics(HAE.US) With Hold Rating
The provided article content is "Document" which is not enough information to create a summary. Therefore, a summary cannot be generated.
Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue
Haemonetics (HAE) projects a 4% to 7% revenue growth for fiscal year 2027. This growth is anticipated to be driven by the continued rollout of its Persona PLUS platform and efforts to rebound its IVT (Interventional Vascular Therapies) business. The company expects these strategic initiatives to contribute to its financial performance in the coming years.
[8-K] HAEMONETICS CORP Reports Material Event
Haemonetics Corporation (NYSE: HAE) has filed an 8-K report detailing its fourth-quarter and fiscal year 2026 financial results, along with its fiscal 2027 guidance. The company reported a net loss of $20.1 million for Q4 2026 due to a significant impairment charge related to Attune Medical, despite achieving revenue growth and strong cash flow. Haemonetics also announced a share repurchase of $100 million and provided fiscal 2027 revenue growth guidance of 4-7% (reported).
Haemonetics: Fiscal Q4 Earnings Snapshot
Haemonetics Corp. (HAE) reported a fiscal fourth-quarter loss of $20.1 million, or 44 cents per share. However, adjusted earnings of $1.29 per share surpassed Wall Street expectations, as did the company's revenue of $346.4 million. For the full year, Haemonetics posted a profit of $97.3 million on revenue of $1.33 billion.
Haemonetics Corp reports results for the quarter ended March 31 - Earnings Summary
Haemonetics Corp has reported its earnings results for the quarter that ended on March 31. This brief summary from Refinitiv was published via TradingView News. The full details are available to users who log in or create an account.
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Haemonetics Corporation announced that its financial results for the fourth quarter of fiscal year 2026, which ended March 28, 2026, are now available on its Investor Relations website. The company will host a conference call and webcast on May 7, 2026, at 8:00 a.m. ET to discuss these results, with a replay available afterward. Supplemental earnings materials are also accessible online.
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Haemonetics Corporation (NYSE: HAE) announced that its fourth-quarter fiscal year 2026 financial results, for the period ending March 28, 2026, are now accessible on the company's Investor Relations website. The company will also host a conference call and webcast on May 7, 2026, at 8:00 a.m. ET, during which they will discuss the results and answer questions from investors and analysts. Supplemental earnings materials are also available on the website.
Earnings call transcript: Haemonetics Q4 2026 beats EPS forecast, stock surges
Haemonetics (HAE) reported strong financial results for Q4 FY2026, surpassing analyst expectations with an adjusted EPS of $1.29 and revenue of $346 million. This positive performance, driven by growth in plasma and blood management technologies and strategic initiatives, led to a 9.51% surge in the company's stock during pre-market trading. The company also provided an optimistic outlook for fiscal year 2027, projecting continued revenue growth and margin expansion, supported by new product launches and sustained market leadership.
Haemonetics: Fiscal Q4 Earnings Snapshot
Haemonetics Corp. (HAE) reported a loss of $20.1 million, or 44 cents per share, in its fiscal fourth quarter, though adjusted earnings of $1.29 per share surpassed analyst expectations. The company also exceeded revenue forecasts, posting $346.4 million for the quarter. For the full year, Haemonetics reported a profit of $97.3 million on revenue of $1.33 billion.
Haemonetics beats Q4 estimates, stock surges on guidance
Haemonetics reported Q4 fiscal 2026 results that exceeded analyst expectations, with adjusted EPS of $1.29 and revenue of $346.4 million. The company's stock surged 17.7% following the strong earnings and positive fiscal 2027 guidance, which projects reported revenue growth of 4% to 7% and adjusted earnings per diluted share growth comparable to revenue growth.
HAEMONETICS ($HAE) Releases Q4 2026 Earnings
HAEMONETICS ($HAE) reported its Q4 2026 earnings, beating analyst estimates with $1.29 per share against a $1.28 estimate, and revenues of $346.35 million against $340.23 million. The article also details recent insider trading, hedge fund activity, government contracts, and analyst ratings and price targets for the company.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) reported strong Q4 earnings of $1.29 per share, exceeding the Zacks Consensus Estimate of $1.28, and revenues of $346.35 million, surpassing the estimate by 2.43%. This marks the fourth consecutive quarter the company has beaten both EPS and revenue estimates. Despite recent underperformance in stock price, investors will look to management's commentary for future guidance, though the stock currently holds a Zacks Rank #4 (Sell).
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Haemonetics (NYSE: HAE) has made its fourth-quarter fiscal 2026 financial results available on its Investor Relations website ahead of a scheduled conference call and webcast on May 7, 2026, at 8:00 a.m. ET. The company's announcement follows a historical pattern of volatile market reactions to its earnings reports, with previous quarters showing significant stock price swings. Key financials and a supplemental presentation are provided online for investors and analysts.
Haemonetics earnings ahead: Can vascular closure rebound?
Haemonetics (NYSE: HAE) is set to release its fourth-quarter fiscal 2026 results, with investors focusing on the potential rebound of its vascular closure business following recent product approvals and acquisitions. Analysts expect earnings of $1.27 per share on revenue of $337.04 million, representing a 7.6% increase in earnings year-over-year. The company's efforts to integrate acquired technologies like Vivasure Medical's PerQSeal Elite and expanded FDA approval for its Vascade MVP XL device are key to its growth strategy in a competitive market segment.
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape
Haemonetics Corp., a small-cap pharmaceutical company, has adjusted its stock valuation, presenting a P/E ratio of 16 and a return on equity of 19.13%. Despite a year-to-date return of -25.03%, the company maintains a favorable financial profile compared to peers like Masimo Corp. and Bio-Rad Laboratories due to strong profitability metrics. This suggests it remains competitively positioned within the industry amidst market fluctuations.
Haemonetics Drops 6.2% Amid Sector-Wide Selling
Haemonetics Corporation experienced a 6.2% plunge in its stock price, closing at $55.60, as a result of a broad sell-off impacting the entire medical devices sector. The decline was not company-specific, with several peers also reporting significant losses, suggesting a macro-economic or sector-wide re-evaluation rather than individual company issues. The high trading volume indicates increased investor activity as they reposition themselves in response to these broader pressures, and investors are advised to monitor whether this sector weakness persists.
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Swings?
This article analyzes Haemonetics (HAE) after recent share price fluctuations, evaluating its current valuation. Using a Discounted Cash Flow (DCF) analysis, the stock appears undervalued by 34.5% compared to its intrinsic estimate. Additionally, its P/E ratio of 15.7x is below the industry average and Simply Wall St's Fair Ratio, further suggesting undervaluation.
Haemonetics director Charles J. Dockendorff not standing for re-election
Haemonetics director Charles J. Dockendorff will not stand for re-election at the 2026 Annual Meeting. He will, however, remain in his director and committee roles until that meeting. The decision is personal and not due to any disagreement with the company.
Earnings Preview: Haemonetics to Report Financial Results Pre-market on May 07
This article announces that Haemonetics (HAE) is scheduled to release its financial results before the market opens on May 7. Analysts expect the company to report earnings of $0.98 per share for the fiscal quarter ending March 2026, with revenue projected at $317.06 million. The report will likely include details on the impact of product portfolio management and operational discipline on profitability.
Haemonetics Announces Upcoming Departure of Longtime Board Director
Haemonetics announced that Charles J. Dockendorff, a board director since 2014, will not seek re-election at the 2026 Annual Meeting of Shareholders. Dockendorff will continue his board and committee roles until the meeting, and his decision is not due to any disagreement with the company. The company, a medical technology provider, has a current market cap of $2.79 billion, and its stock (HAE) is rated a Buy by one analyst with a $70.00 price target.
Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday
Haemonetics (HAE) is expected to report its Q4 2026 earnings before the market open on Thursday, May 7th, with analysts projecting $1.28 EPS and $337.04 million in revenue, and the company forecasting FY2026 EPS to be between $4.90 and $5.00. In the previous quarter, the company surpassed estimates with $1.31 EPS and $338.97 million in revenue. The stock currently holds a "Moderate Buy" rating from analysts with an average price target of $82.78.
Vanguard reports 2.60M-share stake in Haemonetics (HAE) via Schedule 13G
Vanguard Portfolio Management has reported a beneficial ownership of 2,600,145 shares (5.59%) in Haemonetics Corp (HAE) through a Schedule 13G filing. The filing indicates that Vanguard holds sole dispositive power over all 2.60 million shares but only sole voting power for 40,829 shares. This transparency helps inform the public about significant ownership stakes in publicly traded companies.
Skylands Capital LLC Sells 44,894 Shares of Haemonetics Corporation $HAE
Skylands Capital LLC significantly reduced its stake in Haemonetics Corporation ($HAE) by selling 44,894 shares in Q4, cutting its holding by 55.2% to 36,475 shares valued at $2.923 million. Despite this, other institutional investors increased their positions, and 99.67% of the stock is held by such entities. Haemonetics reported strong Q4 earnings, beating expectations, and analysts currently rate the stock as a "Moderate Buy" with an average target price of $82.78.
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Challenges
Haemonetics Corp., a small-cap pharmaceuticals and biotechnology company, has seen a revision in its stock evaluation. Despite a -3.21% return over the past year, its P/E ratio of 16 and ROE of 19.13% suggest effective capital utilization and a competitive valuation compared to industry peers like Masimo Corp. and Bio-Rad Laboratories, Inc. The company's current stock price is $59.93.
